Supplementary Figure 2 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Year: 2023
Type: supplementary-materials
Abstract: Cellular tumor purity for biopsies is greater than 70%. Tumor purity from biopsies was analyzed with the Estimate Package from Bioconductor using R language. The majority (85%) of biopsies have an estimated cellular purity of over 70%, with small differences observed between pre and post-tx biopsies. Patient 17 had both 8-week and 6-months post-tx biopsies. Tx: therapy.
Authors: Roisin M. Connolly, Huili Li, Rachel C. Jankowitz, Zhe Zhang, Michelle A. Rudek, Stacie C. Jeter, Shannon A. Slater, Penny Powers, Antonio C. Wolff, John H. Fetting, Adam Brufsky, Richard Piekarz, Nita Ahuja, Peter W. Laird, Hui Shen, Daniel J. Weisenberger, Leslie Cope, James G. Herman, George Somlo, Agustin A. Garcia, Peter A. Jones, Stephen B. Baylin, Nancy E. Davidson, Cynthia A. Zahnow, Vered Stearns
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361885271
